← FDA DRUG APPROVALS

FDA ANDA · ANDA212955

NALMEFENE HYDROCHLORIDE

Sponsor: KNOA PHARMA

APPLICATION
ANDA212955
TYPE
ANDA
ORIGINAL APPROVAL
2022-02-08
LATEST ACTION
2022-02-08
ROUTE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

NALMEFENE HYDROCHLORIDEPrescription
NALMEFENE HYDROCHLORIDE EQ 2MG BASE/2ML (EQ 1MG BASE/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Approval history

2022-02-08UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →